Wilkinson M, Jacobson W, Wilkinson D A
Brain Res Bull. 1985 May;14(5):493-5. doi: 10.1016/0361-9230(85)90028-0.
DSP4 and xylamine compete with [3H]-naloxone for opiate binding sites with IC50 values of approximately 1 microM. This effect can be blocked by excess naloxone but not by the noradrenaline uptake inhibitors cocaine or desipramine. Other drugs containing the 2-chloroalkylamine structure--phenoxybenzamine, dibenamine, chloroethyl clonidine, the cholinotoxin AF-64 and 2-dimethylaminoethyl chloride--were similarly tested. Phenoxybenzamine and dibenamine were also able to compete with [3H]-naloxone for binding at the opiate receptor. Experiments in vivo demonstrated that DSP4, like other opiates, can rapidly reduce LH secretion in the rat. This effect is prevented by naloxone but not by desipramine. These data suggest the use of caution in interpreting the results of experiments in which DSP4 and xylamine are used as "specific" noradrenergic uptake inhibitors or as neurotoxins.
DSP4和木胺与[3H]-纳洛酮竞争阿片类结合位点,其半数抑制浓度(IC50)值约为1微摩尔。这种效应可被过量的纳洛酮阻断,但不能被去甲肾上腺素摄取抑制剂可卡因或地昔帕明阻断。对其他含有2-氯乙胺结构的药物——酚苄明、双苄明、氯乙基可乐定、胆碱毒素AF-64和2-二甲基氨基乙基氯——进行了类似测试。酚苄明和双苄明也能够与[3H]-纳洛酮竞争在阿片受体上的结合。体内实验表明,DSP4与其他阿片类药物一样,可迅速降低大鼠体内促黄体生成素(LH)的分泌。这种效应可被纳洛酮阻止,但不能被地昔帕明阻止。这些数据表明,在解释使用DSP4和木胺作为“特异性”去甲肾上腺素能摄取抑制剂或神经毒素的实验结果时需谨慎。